Br J Clin Pharmacol 1998; 45: 608–612 Tamoxifen and risk of idiopathic venous thromboembolism Christoph R. Meier & Hershel Jick The Boston Collaborative Drug Surveillance Program, Boston University Medical Center, 11 Muzzey Street, Lexington, MA 02173 Aims To evaluate a possible positive. Each tablet contains 30.4 mg tamoxifen citrate equivalent to tamoxifen 20 mg. For the full list of excipients, see section 6.1. The International Breast Cancer Intervention Study (1), which investigated the use of tamoxifen in the unlicensed indication of breast cancer prevention, revealed that women treated with tamoxifen had an approximately 2.3x increased risk of venous thromboembolism (VTE) than those treated with placebo. The breast cancer drug Tamoxifen might well be marketed with the slogan, If it doesn't kill you, it will cure you -- except that would be an overstatement. User Reviews for Tamoxifen. Also known as: Soltamox. The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care. Ethmoid or there are asking if you are considered to the therapist adopts a disease or dissection. Basal epidermal origin to undergo a blunted response after surgery. Tamoxifen citrate tablets USP, a nonsteroidal antiestrogen, are for oral administration. Each film coated tablet contains Tamoxifen citrate15.2 mg or 30.4 mg equivalent to Tamoxifen 10 mg or 20 mg respectively. The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. It is advisable to closely monitor the INR canadian healthcare tamoxifen and adjust the dose if necessary, - Alcohol and nonsteroidal anti-inflammatory drugs (nsaids) increase the risk canadian healthcare tamoxifen and severity of suffering from ulcers and gastrointestinal bleeding. Tamoxifen competes with endogenous estrogens for receptor sites in breast tissue where the estrogens normally exert their actions. The result is a decrease in the growth of breast tissue and of breast cancer tissue.